article thumbnail

Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges

Journal of Cardiovascular Electrophysiology

It highlights the confluence of two major cardiovascular epidemics, atrial fibrillation and heart failure, with preserved ejection fraction. In these conditions, advances in electrophysiology and heart failure physiology are intertwined and are integrated in this review.

article thumbnail

An approach to fluoroless radiofrequency atrial fibrillation ablation

Frontiers in Cardiovascular Medicine

It can be associated with reduced quality of life and complications such as heart failure and stroke. Additional advantages include providing electrophysiology lab personnel with a lead-free working environment and avoiding radiation exposure for both patients and physicians.

article thumbnail

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice

Frontiers in Cardiovascular Medicine

Background Sacubitril/valsartan (SacVal) has been shown to improve the prognosis of heart failure; however, whether SacVal reduces the occurrence of atrial fibrillation (AF) in heart failure has not yet been elucidated.

article thumbnail

Ion channel trafficking implications in heart failure

Frontiers in Cardiovascular Medicine

Heart failure (HF) is recognized as an epidemic in the contemporary world, impacting around 1%–2% of the adult population and affecting around 6 million Americans. Among the most serious manifestations associated with HF is arrhythmia due to the electrophysiological changes within the cardiomyocyte.

article thumbnail

Heart failure with preserved ejection fraction and atrial fibrillation: clinical management in the context of recent therapeutic advances in heart failure and electrophysiology

Frontiers in Cardiovascular Medicine

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.

article thumbnail

A fascinating electrophysiology case. What is this wide complex tachycardia, and how best to manage it?

Dr. Smith's ECG Blog

Slow VT below the detection rate of the ICD lead to worsening heart failure and low stroke volume. Post conversion of VT the patient had low output cardiac failure and became unstable and hypoperfused. Cardiac output (CO) was being maintained by the tachycardia. After atrial rhythm/SR was restored the patient slowly improved.

article thumbnail

Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts

Frontiers in Cardiovascular Medicine

Background The use of SGLT-2 inhibitors has revolutionized heart failure therapy. In the presence of pinacidil induced arrhythmogenicity, neither SGLT2 inhibitor had a significant impact on cardiac electrophysiology. Conclusion In this model, empagliflozin and dapagliflozin demonstrated opposite antiarrhythmic properties.